Semaglutide & Dementia Risk: 7 Million Patient Study
- Semaglutide, a drug used in diabetes and weight-loss treatments, may offer a reduced risk of dementia for individuals with type 2 diabetes, according to case Western Reserve School...
- The study, published in the Journal of Alzheimer's Disease, examined electronic health records of nearly 1.7 million patients with type 2 diabetes over three years.
- Rong Xu, a biomedical informatics professor who led the research, said the team used a statistical method to emulate a randomized clinical trial.
Semaglutide, a drug commonly used for type 2 diabetes and weight loss, shows a promising link to reduced dementia risk for those with type 2 diabetes. A groundbreaking study analyzing nearly 1.7 million patient records revealed this crucial connection between the primary_keyword semaglutide and the secondary_keyword dementia. Published in the ”Journal of alzheimer’s Disease,” the research indicated a considerably lower risk of Alzheimer’s-related dementia among patients using semaglutide compared to other diabetes medications. This could be a game-changer. The study,led by Case Western Reserve researchers,emphasizes the need for further clinical trials. for more insights, check out News Directory 3; we’re dedicated to keeping you at the forefront of medical breakthroughs that impact your health. Discover what’s next …
Semaglutide May Reduce Dementia Risk in Type 2 Diabetes patients
Updated June 28, 2025
Semaglutide, a drug used in diabetes and weight-loss treatments, may offer a reduced risk of dementia for individuals with type 2 diabetes, according to case Western Reserve School of Medicine researchers. Dementia,characterized by declining memory and cognitive function due to brain cell damage,affects over 6 million Americans annually and contributes to more than 100,000 deaths,according to the National Institutes of Health.
The study, published in the Journal of Alzheimer’s Disease, examined electronic health records of nearly 1.7 million patients with type 2 diabetes over three years. The research suggests that patients taking semaglutide showed a significantly lower risk of developing Alzheimer’s disease-related dementia compared to those on other antidiabetic medications. The benefits appeared more pronounced in older adults and women. Semaglutide is a glucagon-like peptide receptor (GLP-1R) molecule that helps regulate blood sugar and reduce hunger.
Rong Xu, a biomedical informatics professor who led the research, said the team used a statistical method to emulate a randomized clinical trial. The analysis compared semaglutide users to those taking seven other common diabetes medications.
Xu emphasized that while the findings are promising regarding semaglutide and dementia prevention, the study’s limitations prevent definitive conclusions.
“There is no cure or effective treatment for dementia, so this new study provides real-world evidence for its potential impact on preventing or slowing dementia development among at-high risk population,” said Xu, who also directs the School of Medicine’s Center for AI in Drug Discovery.
What’s next
Xu said further investigation through randomized clinical trials is needed to confirm whether semaglutide can prevent dementia.